Biotech

7 articles tagged "Biotech"

Anthropic Acquires Biotech Startup Coefficient Bio in $400M Stock Deal

Anthropic has acquired Coefficient Bio, a stealth-mode biotech startup, in a $400 million all-stock transaction — marking the AI company's most significant strategic expansion beyond language models into life sciences, potentially targeting drug discovery and genomic analysis.

D.O.T.S AI NewsroomApr 6, 20263 min read

Startups

Anthropic Acquires Biotech AI Startup Coefficient Bio for $400 Million in Stock

Anthropic has purchased Coefficient Bio, a stealth-stage biotech AI company, in a $400 million all-stock transaction. The acquisition marks the company's most significant move yet into life sciences and signals Anthropic's ambition to apply frontier AI to drug discovery and biological research at scale.

D.O.T.S AI NewsroomApr 5, 2026

Startups

Anthropic Spends $400M in Stock to Acquire an Eight-Month-Old AI Pharma Startup

In its most aggressive move into life sciences to date, Anthropic has acquired Coefficient Bio — a stealth AI drug discovery startup with fewer than ten employees — for $400 million in stock, signaling the company's ambitions to apply Claude's reasoning capabilities directly to pharmaceutical research.

D.O.T.S AI NewsroomApr 5, 2026

Startups

Anthropic Acquires Stealth Biotech AI Startup Coefficient Bio for $400M

Anthropic has purchased Coefficient Bio, a stealth-mode biotech AI startup, in a $400 million all-stock deal — marking the company's most significant move yet beyond language models and into applied life sciences.

D.O.T.S AI NewsroomApr 4, 2026

Research

Mantis Biotech Is Building 'Digital Twins' of Humans to Solve Medicine's Training Data Problem

Mantis Biotech generates synthetic medical datasets — 'digital twins' of the human body — to supply AI training data that real patient records cannot legally or practically provide. The approach targets one of healthcare AI's most persistent bottlenecks: the gap between what AI systems need to learn and what hospitals can share.

D.O.T.S AI NewsroomMar 31, 2026

Industry

Eli Lilly Bets $2.75 Billion on AI Drug Discovery in Landmark Insilico Medicine Deal

US pharmaceutical giant Eli Lilly has signed a $2.75 billion licensing and collaboration agreement with Insilico Medicine, the Hong Kong-listed AI drug discovery company, in one of the largest AI-pharma deals ever recorded. The agreement validates the commercial maturity of AI-driven drug design after years of proof-of-concept claims.

D.O.T.S AI NewsroomMar 31, 2026

Startups

Eli Lilly Signs $2.75 Billion Deal With AI Drug Developer Insilico Medicine

The pharmaceutical giant's landmark deal with the Hong Kong-listed AI biotech firm signals that big pharma is ready to write nine-figure checks for computational drug discovery — and that Insilico's AI-first pipeline has cleared a critical credibility threshold.

D.O.T.S AI NewsroomMar 30, 2026